Wr
023 76? /
JAN 27 2003
Attachment 4
510(K) Summary of Safety and Effectiveness
This 510(K) Summary of Safety and Effectiveness for the Q-YAG™ Nd:YAG Laser
System is submitted in accordance with the requirements of Safe Medical Device Act
(SMDA) of 1990 and follows the Office of Device Evaluation (ODE) guidance
concerning the organization and content of a 510(K) summary.
Applicant: Palomar Medical Technologies, Inc.
Address: 82 Cambridge St.
Burlington, MA 01803
Contact Person: Marcy Moore
Telephone: 919-363-2432
Preparation Date: 11/25/02
Device Trade Name: Palomar Q-YAG™ Nd:YAG Laser System
Common Name: Q:Switched Nd:YAG
Classification Name: Laser surgical instrument for use in General and
Plastic Surgery and in Dermatology
(see: 21 CFR 878-4810).
Product Code: GEX
Panel: 79
Legally-Marketed Predicate Device: ThermoLase SoftLight
K971207
System Description: The complete system consists of a power supply
unit, a cooling unit, a foot switch, and the hand
piece that connects the laser unit and cooling unit
using an umbilical cord. In standard use, the hand
piece is held against the treatment area and the light
pulse is delivered when the foot switch and hand
/ switch is depressed. Laser parameters and other
system features are controlled from a display panel
located on the front of the power supply unit.
14

KO232962 42

Intended Use of the Device: The Palomar Q-YAG™ is indicated for laser skin
resurfacing with or without adjuvant
preparation.

Performance Data: The differences in the specifications of the
laser and the predicate device do not result in
different performance or raise new questions of
safety or efficacy.

Conclusion: Based on the foregoing, the Palomar Q-YAG™
Nd:YAG Laser System is substantially equivalent to
the legally-marketed claimed predicate device, i.e.,
the Thermolase SoftLight.

15

—_
i Ra DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
% ae
“oe JAN 2 7 2003 Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
Palomar Medical Technologies, Inc.
Marcy Moore
Manager of Clinical Studies
131 Kelekent Lane
Cary, North Carolina 27511
Re: K023967
Trade/Device Name: Palomar Q-YAG™ Nd:YAG Laser System
Regulation Number: 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic
surgery and in dermatology
Regulatory Class: Class I]
Product Code: GEX
Dated: November 27, 2002
Received: November 29, 2002
Dear Ms. Moore:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA):
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of — ‘
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class IT (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing

Page 2— Ms. Marcy Moore
(21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). Other general
information on your responsibilities under the Act may be obtained from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address
http://www. fda.gov/cdrh/dsma/dsmamain. html
Sincerely yours,
Munuam C Pernt
& Cotia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure

INDICATION FOR USE STATEMENT
é
510(K) Number: E o 4 3 qe / . —
: Device Name: Palomar Q-YAG™ Nd:YAG Laser System
Indications for Use: ,
The Palomar Q-YAG™ Nd:YAG laser system is indicated at the 1064 nm
wavelength for skin resurfacing with or without adjuvant preparation.
(Please do not write below this line - Continue on another page if needed)
Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use nw OR Over-the-Counter Use
(per 21 CFR 801.109)
onsion Sica-OH
“Undaion of Gene 1. Restorative
ud Neurologica: ‘ svices
9

